Research Type: Reports

  • Xeljanz, the FDA, and nine years of patient harm

  • Atypical antipsychotics: Decades of use, unfathomable harms

  • Medicare Part B Premium Dynamics Explained

  • Comparing Factors that Influence Pharmaceutical Pricing and Access in the US and five other Countries

  • Biosimilars in Medicare Part D: pricing dynamics and considerations

  • Evaluating Industry’s Drug Pricing Claims

  • Production Plus Profit Pricing (P-quad) FAQ

  • Biosimilars: Market Changes do not equal policy success

  • Ethics of Clinical Trials to Evaluate Biosimilars

  • Bottom-Up Pricing Estimate for P-quad